IO Biotech retains Raymond James, implements cost-cutting measures.

viernes, 30 de enero de 2026, 4:56 pm ET1 min de lectura
IOBT--

IO Biotech has retained Raymond James & Associates as its exclusive financial advisor to explore strategic alternatives. The company is also implementing cost-containment measures, including a reduction in force, to reduce operating expenses while exploring options. IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios